Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AtriCure (ATRC) stocks in Canada

Learn how to easily invest in AtriCure stocks.

AtriCure Inc
- $1.64 ( - 2.58%)

AtriCure is a medical instruments & supplies business based in the US. AtriCure stocks (ATRC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $81.5 – a decrease of 4.93% over the previous week. AtriCure employs 750 staff and has a trailing 12-month revenue of around $258.8 million.

How to buy shares in AtriCure

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATRC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

AtriCure stock price (NASDAQ:ATRC)

Use our graph to track the performance of ATRC stocks over time.

AtriCure shares at a glance

Information last updated 2022-01-16.
Latest market close$63.63
52-week range$55.77 - $89.18
50-day moving average $71.56
200-day moving average $73.81
Wall St. target price$99.00
PE ratio 65.9013
Dividend yield N/A (0%)
Earnings per share (TTM) $0.99

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy AtriCure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

AtriCure price performance over time

Historical closes compared with the close of $63.63 from 2022-01-19

1 week (2022-01-12) -6.97%
1 month (2021-12-17) -6.18%
3 months (2021-10-16) N/A
6 months (2021-07-20) -19.87%
1 year (2021-01-20) 11.24%
2 years (2020-01-17) 66.35%
3 years (2019-01-18) 100.54%
5 years (2017-01-20) 321.39%

Is AtriCure under- or over-valued?

Valuing AtriCure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AtriCure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AtriCure's P/E ratio

AtriCure's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 66x. In other words, AtriCure shares trade at around 66x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

AtriCure financials

Revenue TTM $258.8 million
Gross profit TTM $149.3 million
Return on assets TTM -3.94%
Return on equity TTM 10.02%
Profit margin 17.53%
Book value $10.63
Market capitalisation $3 billion

TTM: trailing 12 months

AtriCure share dividends

We're not expecting AtriCure to pay a dividend over the next 12 months.

AtriCure share price volatility

Over the last 12 months, AtriCure's shares have ranged in value from as little as $55.77 up to $89.18. A popular way to gauge a stock's volatility is its "beta".

ATRC.US volatility(beta: 1.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AtriCure's is 1.1526. This would suggest that AtriCure's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

AtriCure overview

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site